D. Western Therapeutics Institute, Inc. (4576.T)
JPY 113.0
(-0.88%)
JPY 113.0
(-0.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.37 Billion JPY | -19.72% |
| 2022 | 2.95 Billion JPY | 20.04% |
| 2021 | 2.46 Billion JPY | -10.04% |
| 2020 | 2.73 Billion JPY | 38.17% |
| 2019 | 1.98 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.06 Billion JPY | -2.44% |
| 2024 Q1 | 2.11 Billion JPY | -10.79% |
| 2023 Q4 | 2.37 Billion JPY | -9.64% |
| 2023 FY | 2.37 Billion JPY | -19.72% |
| 2023 Q3 | 2.62 Billion JPY | -6.88% |
| 2023 Q2 | 2.82 Billion JPY | -1.11% |
| 2023 Q1 | 2.85 Billion JPY | -3.51% |
| 2022 Q4 | 2.95 Billion JPY | -3.29% |
| 2022 Q3 | 3.05 Billion JPY | 0.0% |
| 2022 FY | 2.95 Billion JPY | 20.04% |
| 2021 FY | 2.46 Billion JPY | -10.04% |
| 2020 FY | 2.73 Billion JPY | 38.17% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 63.982% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -95.915% |
| GNI Group Ltd. | 62.39 Billion JPY | 96.196% |
| Linical Co., Ltd. | 18.53 Billion JPY | 87.199% |
| Trans Genic Inc. | 9.81 Billion JPY | 75.809% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 57.875% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 65.832% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 59.195% |
| AnGes, Inc. | 28.89 Billion JPY | 91.786% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -173.658% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.49% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -46.633% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 53.2% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 45.438% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 2.445% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 65.754% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -35.509% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 53.331% |
| PeptiDream Inc. | 67.12 Billion JPY | 96.464% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -16.308% |
| Ribomic Inc. | 3.54 Billion JPY | 33.093% |
| SanBio Company Limited | 5.04 Billion JPY | 52.977% |
| Healios K.K. | 15.15 Billion JPY | 84.339% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -92.917% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 21.307% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -60.999% |
| StemRIM | 9.08 Billion JPY | 73.862% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 65.502% |
| FunPep Company Limited | 2.49 Billion JPY | 4.727% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 9.367% |
| Stella Pharma Corporation | 3.82 Billion JPY | 37.88% |
| TMS Co., Ltd. | 3.55 Billion JPY | 33.234% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 58.931% |
| Cuorips Inc. | 6.18 Billion JPY | 61.625% |
| K Pharma,Inc. | 3.31 Billion JPY | 28.381% |
| Takara Bio Inc. | 123.2 Billion JPY | 98.074% |
| ReproCELL Incorporated | 9.05 Billion JPY | 73.783% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 12.593% |
| StemCell Institute Inc. | 6.54 Billion JPY | 63.727% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 66.04% |
| CellSeed Inc. | 2.46 Billion JPY | 3.747% |